AbCheck pockets pharma deal
Plzen – Czech antibody discovery and development specialist AbCheck s.r.o. has signed its first contract with a big pharma company. In October, the yearling Czech spin-off from German antibody drug developer Affimed GmbH announced an antibody discovery deal with Eli Lilly and Company. Under the terms of the agreement, AbCheck will use its three antibody discovery libraries, which are comprised of 10 billion structurally diverse proteins, to deliver fully human antibodies against diverse IgM, semi-synthetic and fully synthetic library display antibodies as scFv on the surface of phage particles. Lilly will receive all rights concerning the antibodies from AbCheck, which in return will receive discovery fees and development milestones totalling an undisclosed amount, according to the contract negotiated with IP consultants from Freshfields Bruckhaus Deringer. The Plzen-based antibody service company took over IP antibody discovery processes – from early stage research to lead optimisation – from Affimed, which is focussed on developing its pipeline of preclinical tetravalent monoclonal antibody drugs.